Its time for On-Point, where we speak to experts to delve deeper into some of the key issues in the spotlight right now. South Korea was able to finally approve its first domestically produced COVID-19 vaccine with SKYCovione, developed by SK Bioscience. Its certainly a huge step forward in the countrys push towards easing its dependence on imported vaccines.
But, how effective is SKYCovione, and will it be enough to convince South Koreans to continue to get vaccinated towards the tail end of the pandemic.
Well find out, as we connect with Dr. Kim Seung-taek, Virologist at the Zoonotic Virus Lab at Institut Pasteur Korea. Good morning to you.
Firstly, can you tell us about SKYCovione, when it comes to its efficacy, and how its administered?
When it comes to flu vaccines, I know more people are keen on getting vaccinated using domestically-made vaccines. Do you think itll be the same with this vaccine?
Some argue that SKYCovione was quite late to market, with vaccines like Pfizer and Moderna already dominating. Do you think there will be a continued demand for COVID-19 vaccines in the future?
Whats next now that South Korea does indeed have its own domestically produced COVID-19 vaccines? Will it open doors to bigger things for South Korea?
Thanks for your insights. Looking forward to speaking to you again.